Penumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial

Project Information

PROOF

Grant agreement ID: 733379

DOI

10.3030/733379

Project closed

EC signature date 12 December 2016

Start date 1 January 2017

End date 30 June 2023

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 5 247 102,54

EU contribution

€ 5 246 831,94

Coordinated by

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (3)

PROOF exploitation strategy

This documents summarises the steps towards a PROOF exploitation strategy until M30 IMC set up M6 awarenessraising workshop on IP management M12 identification and information of relevant stakeholders M12 first IMC report including draft efficacy and safety case for the exploitation strategy M30

Final list of participating centres

Final list of participating centres.

PROOF communication and dissemination tools

This document summarises all communication and dissemination tools established during the first year: Press release at the time of the kick-off meeting (M1), graphic standards (M3), provisional public website goes live (M3), presentation leaflet and poster (M6), PROOF PowerPoint presentation (M6), PROOF website fully functional, including a secure intranet area (M6).

Other (1)

DSMB Formation

Data and Safety Monitoring Board Formation.

Publications

Peer reviewed articles (1)

Normobaric hyperoxygenation: a potential neuroprotective therapy for acute ischemic stroke?

Author(s): Sven Poli, Jean-Claude Baron, Aneesh B. Singhal, Florian Härtig
Published in: Expert Review of Neurotherapeutics, Issue 17/12, 2017, Page(s) 1131-1134, ISSN 1473-7175
Publisher: Future Drugs Ltd.
DOI: 10.1080/14737175.2017.1376657